McKesson Corp

Stage 2 uptrend remains in force with structural repair confirmed by the Bullish Pivot Point and rising EMAs. Active Lockout Rally dynamics indicate continued institutional demand, allowing participation despite extreme overbought readings. Medium- and Long-term biases are bullish, and execution favors continuation participation above recent highs into the extension.

• ↑12% YoY revenue growth to $403B, driven by oncology and specialty.
• ↑Adjusted EPS rose 18% YoY to $39.11 in fiscal 2026.
• ↓Potential IRA impacts create reimbursement and pricing uncertainties.